Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
01 Giugno 2023 - 7:30AM
Sanofi launches 2023 global Employee Stock Purchase Plan
Paris,
June 1 2023.
Sanofi launches Action 2023, its global employee shareholder plan,
open to around 86,000 employees in 56 countries. The program builds
on plans carried out since 2013 and demonstrates the ongoing
commitment of Sanofi and its Board of Directors to involve all
employees, across all its territories, in the future development
and results of the company.
Paul HudsonChief Executive
Officer of Sanofi "This plan represents our desire to unite
employees around a collective company performance, enabling them to
feel truly invested in our growth story. Together with the Board of
Directors, we believe the year over year increase in the plan’s
participation clearly shows the commitment of our employees to the
long-term success of Sanofi and our ambition to transform the
practice of medicine.”
Starting June 5th , the shares will be offered
at a subscription price of 79,58€, which is equal to a 20% discount
on the average of the 20 opening prices of Sanofi shares from May 3
to May 30th, 2023. For every five shares subscribed, employees will
be able to receive one free matching share (up to a maximum of four
matching shares per employee). Each employee will be able to
purchase up to 1,500 Sanofi shares within the legal limit of a
maximum payment amount that does not exceed 25% of their gross
annual salary, minus any voluntary deductions already made under
employee savings schemes (Group Savings Plan and/or Group
Retirement Savings Plan) during the year 2023.
In 2022, the employee share ownership plan was
open to over 85,000 employees in 59 countries with a growing
overall uptake rate of 38.5% (vs 37.5% in 2021). More than 32,800
Sanofi employees chose to invest in the company. Today, nearly
75,000 current or former employees of the company are shareholders
of Sanofi, and hold approximately 2%1 of its capital.
Detailed conditionsAn eligibility condition of
three months employment by the closing date of the offer period
will apply. Eligible staff will be able to subscribe shares 5th
June 2023 (inclusive) to 23rd June 2023 (inclusive). The issue is
expected to be completed and the delivery of the securities carried
out by the end of July 2023.The maximum number of Sanofi shares
that may be issued under this offer is 10,580,415 shares
(corresponding to a maximum capital increase of €21,160,831 at
nominal value, being 1% of share capital less the amount of the
capital increase carried out on July 26th, 2022) The new shares,
including the matching shares (the "Shares"), will be subscribed
(or delivered) either directly or through the intermediary of
employee mutual funds ("FCPE"), depending on the regulations and/or
tax regime applicable in the various countries of residence of
those eligible for the capital increase.
The Shares will be fully fungible with the
existing ordinary shares comprising the share capital of Sanofi and
will acquire dividend rights as from 1 January 2023.The voting
rights attached to the subscribed Shares will be exercised directly
by the employees. Those taking up this offer will be required to
hold the Shares or the corresponding FCPE units for a period of
approximately five years, i.e. until 31 May 2028, except upon the
occurrence of an early release event provided for under Article R.
3324-22 of the French Labour Code and authorized in the
subscriber's country. Admission of the Shares to trading on the
Euronext Paris market (ISIN Code: FR0000120578 ) on the same line
as the existing shares will be requested as soon as possible after
the completion of the capital increase.This press release does not
constitute an offer to sell or a solicitation to buy Sanofi shares.
The offer of Sanofi shares reserved for employees will only be made
in countries where such an offer has been registered with or
notified to the competent local authorities and/or following the
approval of a prospectus by the competent local authorities, or in
consideration of an exemption from the requirement to prepare a
prospectus or to register or notify of the offer, where such
procedure is required.More generally, the offer will only be made
in countries where all required registration and/or notification
procedures have been carried out, approvals obtained, and
procedures for consulting or informing employee representatives
followed.This press release is not intended for and should not be
copied to or distributed in countries where such a prospectus has
not been approved or such exemption is not available or where all
necessary registration, notification, consultation and/or
information procedures have not been completed or authorisations
obtained. This relates in particular to Japan, Morocco, Tunisia and
the Philippines, where to date formalities are still pending with
the authorities but could also relate to other countries.
This press release is prepared in accordance
with the exemption from publication of a prospectus under Article 1
4°i) and 5°h) of the Prospectus Regulation (EU) 2017/1129. It
constitutes the document required to meet the conditions for
exemption from publication of a prospectus as defined by the
Prospectus Regulation.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.comEvan Berland | +1
215 432 0234 | evan.berland@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69
36 93 | arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
1 Via employee Savings plan (PEG) and shares
held directly by present employees
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024